# Edwards Lifesciences Moat

Status: published. Policy: company-analysis-1.

Edwards has a demonstrated intangible-assets advantage built on accumulated clinical evidence, approved therapies, proprietary technology and sustained commercial adoption, especially in TAVR. These support a narrow moat; the passages do not establish exceptional durability against established competitors. Stable global TAVR selling prices in both reported 2026 quarters demonstrate price resilience, but not broad pricing freedom. Competitive innovation, reimbursement constraints, shared intellectual property and actual litigation costs limit protection.

## intangible_assets

Accumulated clinical evidence, regulatory approvals and proprietary valve technology create a meaningful replication burden and support current adoption. SAPIEN's disclosed clinical history and treated population, commercial availability of newer therapies and multiyear product sales establish more than pipeline potential. Clinical superiority versus surveillance does not establish superiority versus competing devices.

Durability: Commercialization since 2007 in Europe, an extensive clinical record and continuing product launches support persistence over multiple years. Maintaining the advantage requires continued evidence generation and innovation. Patent expiration dates and the duration of comparative product advantages are not established.

Risks: Medtronic and Abbott compete across relevant product groups. Mutual patent access with Medtronic limits exclusivity and entails royalties. Technology substitution, reimbursement pressure and hospital capacity constraints can impair adoption. Litigation expenses and investment impairments are realized costs; generic obsolescence risks are possibilities. Recent growth also benefited from an unnamed competitor's exit.

Invalidation: The thesis would weaken materially if competing approved devices matched Edwards' clinical evidence and outcomes while causing sustained loss of physician demand or competitive position, if approvals or adverse clinical findings restricted core products, or if persistent price concessions and royalty burdens prevented Edwards from monetizing its differentiation.

Competitors: Medtronic plc, Abbott Laboratories
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm) · 2026-02-25
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htm) · 2026-08-04
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm) · 2026-03-26
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980025000005/ew-20241231.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980025000005/ew-20241231.htm) · 2025-02-28
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980024000004/ew-20231231.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980024000004/ew-20231231.htm) · 2024-02-12
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000026/ew-20260331.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000026/ew-20260331.htm) · 2026-05-06
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ex-991q22026.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ex-991q22026.htm) · 2026-07-23
- [https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ex-991q12026.htm](https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ex-991q12026.htm) · 2026-04-23

[JSON](https://beanvest.com/stock/ew/moat.json)